InvestSMART

Pharmaxis Ltd (ASX: PXS) - Announcements

- Current share price for PXS : $0.027

ASX company news and announcements for Pharmaxis Ltd (PXS) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Pharmaxis Ltd (PXS) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Pharmaxis Ltd (PXS), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Pharmaxis Ltd (PXS)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Trading Halt 2 Jun 2009 9:28AM $2.630 $0.027 fallen by 98.97%
- US FDA Accepts Aridol New Drug Application for Review 14 May 2009 9:00AM $2.500 $0.027 fallen by 98.92%
- Pharmaxis Announces Positive Results of Phase 3 CF Trial 4 May 2009 4:12PM $2.280 $0.027 fallen by 98.82%
- Trading Halt 4 May 2009 9:50AM $2.280 $0.027 fallen by 98.82%
- Appendix 4C - quarterly 8 Apr 2009 4:30PM $2.150 $0.027 fallen by 98.74%
- Pharmaxis Announces Milestone in Phase III Trial for CF 1 Apr 2009 9:20AM $1.710 $0.027 fallen by 98.42%
- Pharmaxis Appoints French Distributor for Aridol 11 Mar 2009 4:19PM $1.275 $0.027 fallen by 97.88%
- Aridol New Drug Application Submitted to FDA 2 Mar 2009 8:22AM $1.250 $0.027 fallen by 97.84%
- Half Yearly Report - December 2008 6 Feb 2009 8:48AM $1.280 $0.027 fallen by 97.89%
- Appendix 4C - quarterly 28 Jan 2009 4:47PM $1.445 $0.027 fallen by 98.13%
- Pharmaxis Aridol Approved for Sale in Switzerland 20 Oct 2008 9:12AM $1.550 $0.027 fallen by 98.26%
- Appendix 4C - Quarterly Cash Flow 15 Oct 2008 5:00PM $1.550 $0.027 fallen by 98.26%
- Pharmaxis Files Aust Marketing Application for Bronchitol 1 Oct 2008 9:28AM $2.180 $0.027 fallen by 98.76%
- 12 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectas 20 Aug 2008 11:31AM $1.990 $0.027 fallen by 98.64%
- Preliminary Final Report 13 Aug 2008 8:32AM $1.990 $0.027 fallen by 98.64%
- Bronchitol Cystic Fibrosis Dose Trial Results Positive 12 Aug 2008 8:39AM $1.930 $0.027 fallen by 98.60%
- Appendix 4C - quarterly 23 Jul 2008 4:38PM $1.730 $0.027 fallen by 98.44%
- Pharmaxis Concludes Special Protocol Assessment with FDA 20 Jun 2008 8:27AM $1.620 $0.027 fallen by 98.33%
- Pharmaxis Establishes Named Patient Program for Bronchitol 17 Jun 2008 10:10AM $1.595 $0.027 fallen by 98.31%
- Long-term safety study of Bronchitol completes 12 Jun 2008 9:09AM $1.510 $0.027 fallen by 98.21%
- Pharmaxis` Aridol Authorised for Sale in Germany 19 May 2008 11:12AM $1.590 $0.027 fallen by 98.30%
- Regulatory Path for Bronchitol in Bronciectasis 1 May 2008 6:26PM $1.770 $0.027 fallen by 98.47%
- Appendix 4C - quarterly 15 Apr 2008 5:48PM $1.780 $0.027 fallen by 98.48%
- March 2008 Quarterly Report to Shareholders 15 Apr 2008 4:18PM $1.780 $0.027 fallen by 98.48%
- Cystic Fibrosis Trial in Children Returns Positive Data 4 Apr 2008 11:08AM $2.490 $0.027 fallen by 98.92%

726 - 750 of 836 results

Page 30 of 34

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.